Those are things the boards can ask you. You can practice spitting out these numbers when you see patients in consults to help you learn the data. For instance, if you have a high-risk prostate cancer consult coming up, you look up the treatment paradigm, and a take a look at the numbers from studies like, BFFS, 5 and 10-yr OS, toxicity. Patients will often ask "what are my chances of beating this" or "what are my chances of getting erectile dysfunction" and these numbers can give you something to go off of and are fair game for testing. May also come in handy for tumor boards.
There are a lot of studies for prostate cancer, because CaP is such a spectrum from very-low risk, to very-high risk, node positive, metastatic and post-op and so many modalities to treat with. But, hopefully at your institution, you will also encounter a lot of prostate cancer patients, which will give you more opportunities to learn while seeing patients. As opposed to seminoma, which seems to be commonly tested as well, but I only saw patients in the metastatic setting as a resident. Also, for that particular book, some sections are better than others at highlighting the important studies. Prostate was good overall, but the endometrial section had a few lower yield studies included.